FDA approves Lilly’s once-weekly insulin Onswik for type 2 diabetes

Eli Lilly announced on September 24 that the U.S. Food and Drug Administration has approved Onswik, its once-weekly basal insulin, for adults with type 2 diabetes. The decision adds an option that substantially reduces injection frequency while delivering blood-sugar control comparable to established daily basal insulins in clinical trials.

Lilly’s U.S. healthcare-professional website dates the approval to September 23, 2026. The medicine, insulin efsitora alfa-gobe, is indicated alongside diet and exercise to improve glycemic control. The company says the supporting QWINT phase 3 program evaluated more than 3,400 adults with type 2 diabetes.

For people managing a chronic metabolic disease over many years, treatment burden matters. But the evidence supporting this approval concerns glucose control and safety; it does not establish that weekly insulin extends lifespan or prevents more cardiovascular events than daily alternatives.

What the randomized trials found

Two published studies help explain the evidence behind the announcement. Their results predate this week’s regulatory development.

QWINT-1, published in the New England Journal of Medicine in 2025, randomly assigned 795 adults with type 2 diabetes who had never received insulin to weekly efsitora or daily insulin glargine. The phase 3 trial lasted 52 weeks and was open-label, meaning participants and investigators knew which treatment was assigned.

Its primary endpoint was the change in glycated hemoglobin, or HbA1c. The estimated reduction was 1.19 percentage points with efsitora and 1.16 with glargine. The between-group difference was −0.03 percentage points, with a 95% confidence interval from −0.18 to 0.12. Efsitora met the trial’s noninferiority criterion; superiority was not demonstrated.

QWINT-2, published in the same journal in 2024, randomized 928 adults who also had not previously received insulin. This 52-week, open-label trial compared weekly efsitora with daily insulin degludec. HbA1c fell by an estimated 1.26 and 1.17 percentage points, respectively, again meeting the prespecified noninferiority criterion.

Noninferiority means the weekly treatment met a predefined standard for not being unacceptably less effective than its comparator. It does not mean the medicines are identical or that the weekly option is better for every patient.

Low blood sugar remains central

Safety findings require attention to the particular comparator and trial population.

In QWINT-1, the combined rate of clinically significant or severe hypoglycemia was lower with efsitora: 0.50 versus 0.88 events per participant-year with glargine. QWINT-2 did not demonstrate a statistically clear difference for that combined endpoint: rates were 0.58 with efsitora and 0.45 with degludec, with a rate-ratio confidence interval that included no difference.

These results do not justify a blanket claim that weekly insulin causes fewer low-blood-sugar episodes than daily insulin. Lilly’s U.S. product information also states that Onswik is not recommended for type 1 diabetes because of an increased risk of severe hypoglycemia. The new indication is specifically for adults with type 2 diabetes.

What changes—and what remains unanswered

Lilly describes the weekly schedule as reducing basal-insulin injections from approximately 365 to 52 annually. That comparison concerns basal insulin alone. It does not establish that every patient’s entire diabetes regimen becomes a once-weekly treatment; the QWINT program included people who also used mealtime insulin.

The published trials provide controlled comparisons, but both studies discussed here were funded by Lilly and used open-label designs. Their roughly one-year observation periods cannot settle questions about decades of treatment, uncommon harms, or comparative effects on survival.

The practical advance is a less frequent basal-insulin option with replicated evidence of comparable HbA1c reduction. Whether that convenience translates into more consistent treatment and better long-term health in routine care remains an important question after approval.